Los Angeles Capital Management LLC Sells 13,463 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Los Angeles Capital Management LLC lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.6% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 67,399 shares of the biopharmaceutical company’s stock after selling 13,463 shares during the period. Los Angeles Capital Management LLC owned approximately 0.05% of Alnylam Pharmaceuticals worth $21,978,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. SVB Wealth LLC bought a new position in Alnylam Pharmaceuticals in the 1st quarter worth approximately $27,000. Atlantic Union Bankshares Corp acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $30,000. Ameritas Advisory Services LLC bought a new position in Alnylam Pharmaceuticals during the second quarter worth $42,000. AlphaQuest LLC acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $43,000. Finally, Larson Financial Group LLC boosted its holdings in Alnylam Pharmaceuticals by 77.7% in the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 87 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $442.70 on Friday. The stock’s fifty day simple moving average is $458.74 and its 200 day simple moving average is $376.97. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The firm has a market cap of $58.49 billion, a price-to-earnings ratio of -179.23 and a beta of 0.30. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $1.51. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $1.25 billion during the quarter, compared to analysts’ expectations of $943.37 million. During the same period last year, the business earned ($0.50) earnings per share. The business’s revenue was up 149.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on ALNY. Raymond James Financial initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They set an “outperform” rating and a $370.00 price objective for the company. Jefferies Financial Group cut their price target on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a report on Thursday, October 30th. Morgan Stanley lifted their price objective on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a report on Monday, October 6th. Piper Sandler restated an “overweight” rating and set a $489.00 price objective (up from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Finally, Truist Financial raised their target price on Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Twenty-three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $478.67.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Dennis A. Ausiello sold 31,448 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares in the company, valued at approximately $397,724.38. The trade was a 97.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 8,924 shares of the stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the sale, the chief executive officer owned 65,409 shares in the company, valued at approximately $29,568,138.45. This trade represents a 12.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 98,144 shares of company stock valued at $44,160,261. 1.50% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.